<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03219268</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGD013-01</org_study_id>
    <nct_id>NCT03219268</nct_id>
  </id_info>
  <brief_title>A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms</brief_title>
  <official_title>A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zai Lab Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this Phase 1 study is to characterize the safety and tolerability of
      MGD013 and establish the maximum tolerated dose (MTD) of MGD013. Pharmacokinetics (PK),
      immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of MGD013 will also be
      assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, dose escalation and cohort expansion study designed to
      characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary antitumor
      activity of MGD013 administered by IV infusion every 2 weeks. The study consists of a Dose
      Escalation Phase to determine the MTD or maximum administered dose (MAD) of MGD013 if no MTD
      is defined, followed by a Cohort Expansion Phase to further define the safety and initial
      antitumor activity of MGD013 with the dose established in the Dose Escalation Phase.

      In the Dose Escalation Phase, MGD013 will be evaluated in sequential escalating flat doses in
      successive cohorts of 1 to 6 patients each. Upon completion of the Dose Escalation Phase, a
      Cohort Expansion Phase will be initiated at the MTD/MAD.

      Patients with unresectable, locally advanced or metastatic solid tumors of any histology will
      be enrolled in the Dose Escalation Phase. The Cohort Expansion Phase will be limited to
      selected cohorts of patients with unresectable, locally advanced or metastatic solid tumors
      or hematologic malignancies for whom there is no available therapy likely to confer clinical
      benefit. Two additional cohorts will enroll patients with gastric/gastroesophageal cancer or
      epithelial ovarian cancer, with MGD013 given every 3 weeks.

      A separate cohort will evaluate the combination of MGD013 with margetuximab (anti-HER2
      monoclonal antibody) in approximately 99 patients, in subgroups with HER2-positive gastric or
      gastroesophageal cancer, HER2-positive breast cancer, and any other HER2-positive cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2017</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose escalation followed by Cohort Expansion Phase at the MTD.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (MGD013 monotherapy)</measure>
    <time_frame>24 months</time_frame>
    <description>Safety
Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>24 months</time_frame>
    <description>maximum tolerated or maximum administered dose of MGD013</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration versus Time Curve (AUC) of MGD013 and MGD013 plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of MGD013 and MGD013 plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum (peak) plasma concentration (Tmax) of MGD013 and MGD013 plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Ctrough) of MGD013 and MGD013 plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>Ctrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance of the drug from plasma (CL) of MGD013 and MGD013 plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss) of MGD013 and MGD013 plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>Vss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of MGD013 and MGD013 plus margetuximab</measure>
    <time_frame>24 months</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with anti-drug antibody</measure>
    <time_frame>24 months</time_frame>
    <description>immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (MGD013 plus margetuximab)</measure>
    <time_frame>24 months</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Preliminary anti-tumor activity of MGD013 and MGD013 plus margetuximab</measure>
    <time_frame>36 months</time_frame>
    <description>Preliminary anti-tumor activity of MGD013 and MGD013 plus margetuximab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years after end of treatment visit</time_frame>
    <description>Time from start of treatment to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">445</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Hematologic Neoplasms</condition>
  <condition>Gastric Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>GastroEsophageal Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>HER2-positive Gastric Cancer</condition>
  <condition>DLBCL</condition>
  <arm_group>
    <arm_group_label>MGD013</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGD013 administered IV once every 2 or 3 weeks for up to 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MGD013 plus margetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGD013 administered in combination with margetuximab IV once every 3 weeks for up to 32 3-week cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGD013</intervention_name>
    <description>Anti-PD-1, anti-LAG-3 bispecific DART protein</description>
    <arm_group_label>MGD013</arm_group_label>
    <arm_group_label>MGD013 plus margetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGD013 in combination with margetuximab</intervention_name>
    <description>Anti-PD-1, anti-LAG-3 bispecific DART protein plus anti-HER2 monoclonal antibody</description>
    <arm_group_label>MGD013 plus margetuximab</arm_group_label>
    <other_name>MGAH22</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven, locally advanced unresectable or metastatic solid tumors (or
             hematologic malignancies, Cohort Expansion only) for whom no approved therapy with
             demonstrated clinical benefit is available or standard treatment was declined.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy ≥ 12 weeks

          -  Measurable disease

          -  Tissue specimen available for retrospective analysis of PD-1, PD-L1, LAG-3, and MHC-II
             expression

          -  Acceptable laboratory parameters

        HER2+ Cohort:

        - Locally advanced or metastatic HER2+ locally advanced or metastatic solid tumors,
        regardless of organ of origin.

        i. The cancer must have progressed following standard therapy, or has progressed during or
        after HER2-directed therapy if approved and available for patients with HER2+ breast,
        gastric, or gastroesophageal junction cancer.

        ii. History of HER2 positivity defined as 3+ by IHC or 2+ by IHC in combination with in
        situ hybridization (ISH) positivity most recent tumor biopsy.

          -  All patients in the HER2+ cohort must be willing to provide consent for a baseline and
             on-treatment tumor biopsy during the screening period and within 14 days prior to
             Cycle 3 Day 1. Exceptions may be made based on a medical contraindication at the
             discretion of the Sponsor's Medical Monitor. This requirement will be discontinued
             after an adequate number of samples are collected, as determined by the Sponsor.

        Exclusion Criteria:

          -  Symptomatic central nervous system (CNS) metastases or primary CNS lymphoma

          -  History of allogeneic bone marrow, stem-cell, or solid organ transplant

          -  History of known or suspected autoimmune disease with the specific exceptions of
             vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic
             treatment (within the past 2 years), and patients with a history of Grave's disease
             that are now euthyroid clinically and by laboratory testing.

          -  Treatment with any systemic chemotherapy within 3 weeks prior to the initiation of
             study drug; treatment with biologics or investigational therapy within the 4 weeks
             prior to the initiation of study drug.

          -  Major surgery within 4 weeks prior to the initiation of study drug.

          -  Prior treatment with combination of monoclonal antibodies against PD-1 and LAG-3
             (Cohort Expansion only).

          -  Treatment with radiation therapy within 2 weeks prior to the initiation of study drug.

          -  Clinically significant cardiovascular disease.

          -  QTcF prolongation &gt; 480 milliseconds

          -  HER2+ cohort: left ventricular ejection fraction less than 50%

          -  Clinically significant pulmonary compromise, including a requirement for supplemental
             oxygen use to maintain adequate oxygenation.

          -  Active pneumonitis or history of non-infectious pneumonitis.

          -  Clinically significant gastrointestinal disorders.

          -  Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral
             treatment within 7 days prior to the initiation of study drug.

          -  Known history of positive testing for human immunodeficiency virus or history of
             acquired immune deficiency syndrome.

          -  Known history of hepatitis B (except in hepatocellular carcinoma) or hepatitis C
             infection or known positive test for hepatitis B surface antigen, hepatitis B core
             antigen, or hepatitis C polymerase chain reaction (PCR)

          -  Vaccination with any live virus vaccine within 4 weeks prior to the initiation of
             study drug administration. Inactivated annual influenza vaccination is allowed

          -  Dementia or altered mental status that would preclude understanding and rendering of
             informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Sumrow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadia Salem</last_name>
    <phone>202-834-0910</phone>
    <email>salemn@Macrogenics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janine Koucheki</last_name>
    <phone>(240) 224-4457</phone>
    <email>kouchekij@macrogenics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toni Korpela, BSN, RN</last_name>
      <phone>480-256-5464</phone>
      <email>Toni.korpela@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Shakeela Bahadur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carryl Du Bois</last_name>
      <phone>323-865-3084</phone>
      <email>Carryl.DuBois@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khouiery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Seja</last_name>
      <phone>310-794-6892</phone>
      <email>eseja@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Bartosz Chmielowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiomara Menendez</last_name>
      <phone>323-865-3084</phone>
      <email>Xiomara.Menendez@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Howard</last_name>
      <phone>941-377-9993</phone>
      <email>KHoward@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Manish Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Torio</last_name>
      <phone>773-702-1341</phone>
      <email>jtorio@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Hedy Kindler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly White</last_name>
      <phone>410-502-9388</phone>
      <email>kwhite79@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Cesar Santa-Maria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital and Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eamala Sundaram</last_name>
      <phone>617-724-2332</phone>
      <email>sundaram.eamala@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Lipika Goyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Shearin</last_name>
      <phone>919-668-1092</phone>
      <email>sherra.shearin@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jie Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bidwell</last_name>
      <phone>513-636-0087</phone>
      <email>andrea.bidwell@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Robin Norris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center, The University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacie Martin</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>48455</phone_ext>
      <email>stacie-martin@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Susanna Ulahannan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Berry</last_name>
      <phone>215-662-2847</phone>
      <email>alison.berry@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Charu Aggarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle Eaton</last_name>
      <phone>412-623-7957</phone>
      <email>mientkiewiczk@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Luke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madison Kolbe</last_name>
      <phone>615-524-4456</phone>
      <email>Madison.Kolbe@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Destiny Keaton</last_name>
      <phone>713-792-5122</phone>
      <email>DKeaton@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>George Blumenschein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kent</last_name>
      <phone>+61 02 9355 5611</phone>
      <email>Robert.Kent@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Anthony Joshua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerrie Cornall</last_name>
      <phone>(02) 401 43280</phone>
      <email>Kerrie.Cornall@calvarymater.org.au</email>
    </contact>
    <investigator>
      <last_name>Girish Mallesara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care Centre</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Parker</last_name>
      <phone>+61 (0)2 4228 6200</phone>
      <email>suetrials@smdcc.com.au</email>
    </contact>
    <investigator>
      <last_name>Philip Clingan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Health Melbourne</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Coombs</last_name>
      <phone>+61 (0)3 9496 9726</phone>
      <email>nicole.coombs@austin.org.au</email>
    </contact>
    <investigator>
      <last_name>Andrew Weickhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Complex Oncology Center - Burgas&quot; EOOD</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonka Mihneva</last_name>
      <phone>359 877 929 911</phone>
      <email>toni030805@abv.bg</email>
    </contact>
    <contact_backup>
      <last_name>Proletina Tomova</last_name>
      <phone>359 899 849 737</phone>
      <email>pr_tomova@abv.bg</email>
    </contact_backup>
    <investigator>
      <last_name>Krasimir Nikolov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda&quot; EAD, Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Georgieva</last_name>
      <phone>359 878 993 160</phone>
      <email>svetlana.georgieva@acibademcityclinic.bg</email>
    </contact>
    <investigator>
      <last_name>Orechkov Krassimir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Serdika&quot; EOOD, Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Georgieva</last_name>
      <phone>359,877,145,727</phone>
      <email>vg@crinstitute.bg</email>
    </contact>
    <contact_backup>
      <last_name>Neli Tashkova</last_name>
      <phone>359,887,938,418</phone>
      <email>nelly.tashkova@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nadezhda Miteva-Yovcheva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BioVirtus Research Site Sp. Z o.o.</name>
      <address>
        <city>Józefów</city>
        <zip>05-410</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Tomaszewska-Kiecana</last_name>
      <phone>+48 605 206 333</phone>
      <email>monika.kiecana@biovirtus.eu</email>
    </contact>
    <contact_backup>
      <last_name>Karolina Jóźwiak</last_name>
      <phone>+48 695 200 375</phone>
      <email>karolina.jozwiak@biovirtus.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Monika Tomaszewska-Kiecana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Kraków</name>
      <address>
        <city>Kraków</city>
        <zip>31-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sawiec</last_name>
      <phone>+48 604 276 787</phone>
      <email>anna.sawiec@pratia.com</email>
    </contact>
    <investigator>
      <last_name>Monika Dlugosz-Danecka, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Med-Polonia Sp. z o.o.</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Przybysz</last_name>
      <phone>+48 61 656 17 00</phone>
      <email>hanna.przybysz@medpolonia.com.pl</email>
    </contact>
    <contact_backup>
      <last_name>Badań Klinicznych</last_name>
      <phone>+48 61 656 17 00</phone>
      <email>badania.kliniczne@medpolonia.com.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Rodryg Ramlau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy</name>
      <address>
        <city>Warszawa</city>
        <zip>02-034</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Kokoszynska-Brejnakowska</last_name>
      <phone>+48 22 570 92 41</phone>
      <email>kasiakok@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lucjan Wyrwicz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kinga Borkowska</last_name>
      <phone>0048 225463381</phone>
      <email>kinga.borkowska@coi.pl</email>
    </contact>
    <contact_backup>
      <last_name>Honorata Sterczewska</last_name>
      <phone>+48 22 546 33 81</phone>
      <email>honorata.sterczewska@pib-nio.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Iwona Lugowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Analía Azaro, MD</last_name>
      <phone>0034934894350</phone>
      <email>aazaro@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Analía Azaro Pedrazzoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Cortes Castán, MD</last_name>
      <phone>0034913875090</phone>
      <email>jacortes@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Javier Cortes Castán, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Madrid-CIOCC, Hospital HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose de Miguel, MD</last_name>
      <phone>0034917567825</phone>
      <email>maria.demiguel@startmadrid.com</email>
    </contact>
    <investigator>
      <last_name>Maria Jose de Miguel Luken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theerarat Hongcharoen</last_name>
      <phone>(66)2 251 6704</phone>
      <phone_ext>112</phone_ext>
      <email>theerarat.h@chulacrc.org</email>
    </contact>
    <investigator>
      <last_name>Virote Sriuranpong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arawan Larpkitsakul</last_name>
      <phone>(66)53-936-046</phone>
      <phone_ext>601</phone_ext>
      <email>arawanctu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chaiyut Charoentum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suhaila Samursor</last_name>
      <phone>(66) 82-264206589</phone>
      <email>lamoon_blue@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Arunee Dechaphunkul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Cherkasy Regional Oncology Dispensary</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliia Kuchuhurna</last_name>
      <phone>3 80472319418</phone>
      <email>n.kuchuhurna@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Halyna Pylypenko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise &quot;City Clinical Hospital#4&quot; of Dnipro City Council, Chemotherapy Department</name>
      <address>
        <city>Dnipro</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetiana Nikolaieva</last_name>
      <phone>380663182614</phone>
      <email>oncodept.nikolaeva@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Olena Stepanova</last_name>
      <email>estepan0968@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Igor Bondarenko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise &quot;Prykarpatsky Clinical Oncological Centre of Ivano-Frankivska Regional Council&quot;</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariia Peryt</last_name>
      <phone>00380 96 731 34 38</phone>
      <email>mariperit@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anna Kryzhanivska, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise of Sumy Regional Council &quot;Sumy Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Sumy</city>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliia Moskalenko</last_name>
      <phone>380976157396</phone>
      <email>yl.moskalenko@med.sumdu.edu.ua</email>
    </contact>
    <investigator>
      <last_name>Andriy Kurochkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise &quot;Central City Clinical Hospital of Uzhhorod City Council&quot;</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktor Ignatko</last_name>
      <phone>00380 66 150 55 56</phone>
      <email>viktor.ignatko@uzhnu.edu.ua</email>
    </contact>
    <investigator>
      <last_name>Prof. Yevhen Hotko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Podillia Regional Center of Oncology of Vinniza Regional Council</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iryna Matsishevska, MD</last_name>
      <phone>3 80972795074</phone>
    </contact>
    <contact_backup>
      <last_name>Petro Shnaiderman, MD</last_name>
      <phone>3 80972795074</phone>
    </contact_backup>
    <investigator>
      <last_name>Serhiy Shevnia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

